NASDAQ: ATOS

Atossa Therapeutics Inc Stock Forecast, Predictions & Price Target

The consensus among 1 Wall Street analyst covering (NASDAQ: ATOS) stock is to Buy ATOS stock.

Out of 1 analyst, 0 (0%) are recommending ATOS as a Strong Buy, 1 (100%) are recommending ATOS as a Buy, 0 (0%) are recommending ATOS as a Hold, 0 (0%) are recommending ATOS as a Sell, and 0 (0%) are recommending ATOS as a Strong Sell.

If you're new to stock investing, here's how to buy Atossa Therapeutics stock.

(NASDAQ: ATOS) Atossa Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.

Atossa Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ATOS's revenue for 2028 to be $1,741,726,490, with the lowest ATOS revenue forecast at $1,741,726,490, and the highest ATOS revenue forecast at $1,741,726,490. On average, 1 Wall Street analysts forecast ATOS's revenue for 2029 to be $8,483,085,133, with the lowest ATOS revenue forecast at $8,483,085,133, and the highest ATOS revenue forecast at $8,483,085,133.

In 2030, ATOS is forecast to generate $18,106,437,248 in revenue, with the lowest revenue forecast at $18,106,437,248 and the highest revenue forecast at $18,106,437,248.

According to 1 Wall Street analyst that have issued a 1 year ATOS price target, the average ATOS price target is $4.00, with the highest ATOS stock price forecast at $4.00 and the lowest ATOS stock price forecast at $4.00.

The Wall Street analyst predicted that Atossa Therapeutics's share price could reach $4.00 by Apr 2, 2025. The average Atossa Therapeutics stock price prediction forecasts a potential upside of 133.92% from the current ATOS share price of $1.71.